Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Counterfeits Hamper ED Sales In Huge China Market

This article was originally published in PharmAsia News

Executive Summary

Counterfeit copies of the three leading erectile dysfunction drugs are hindering the effort by major pharmaceutical companies to compete in that market in China. Despite a Chinese court case won by Pfizer last year upholding its patent for Viagra (sildenafil), drug makers find their sales are not keeping pace with the 30 percent increase in the Chinese market. Few men in a country with 20 percent of the world's population buy the real ED drugs because cheap copies are readily available. Eli Lilly, maker of Cialis (tadalafil) reports only 1 percent of its global sales comes from China. (Click here for more

Latest Headlines
See All
UsernamePublicRestriction

Register

SC069462

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel